肿瘤细胞治疗研究
英文原题：Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia.
尽管CAR-T细胞疗法作为B细胞恶性肿瘤的治疗手段尤为成功，但利用CAR有效治疗急性髓系白血病仍面临更大挑战。
尽管CAR-T细胞疗法作为B细胞恶性肿瘤的治疗方法特别成功，但用CAR有效治疗急性髓系白血病仍是一个更大的挑战。目前正在进行多项临床前研究和临床试验，包括针对CAR-T细胞可以靶向的AML相关表面标志物，如CD123、CD33、NKG2D、CLL1、CD7、FLT3、Lewis Y和CD70，这些都为开发具有更高特异性和疗效的CAR-T疗法提供了机会。我们还探索了CAR-T细胞治疗AML的具体策略，包括免疫检查点、自杀基因、双靶向、基因组工具以及通用CAR的潜力。此外，CAR-T细胞治疗AML仍存在一定的风险和挑战，包括细胞因子释放综合征（CRS）和血液毒性。尽管存在这些挑战，作为AML治疗的一种新靶向方法，CAR-T细胞疗法仍有很大的前景。正在进行的研究旨在进一步优化这种治疗模式。
Although CAR-T cell therapy has been particularly successful as a treatment for B cell malignancies, effectively treating acute myeloid leukemia with CAR remains a greater challenge. Multiple preclinical studies and clinical trials are underway, including on AML-related surface markers that CAR-T cells can target, such as CD123, CD33, NKG2D, CLL1, CD7, FLT3, Lewis Y and CD70, all of which provide opportunities for developing CAR-T therapies with improved specificity and efficacy. We also explored specific strategies for CAR-T cell treatment of AML, including immune checkpoints, suicide genes, dual targeting, genomic tools and the potential for universal CAR. In addition, CAR-T cell therapy for AML still has certain risks and challenges, including cytokine release syndrome (CRS) and haematotoxicity. Despite these challenges, as a new targeting method for AML treatment, CAR-T cell therapy still has great prospects. Ongoing research aims to further optimize this treatment mode.
MEMBER ACCOUNT
登录成功会直接打开下一页。
